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ABSTRACT
A novel series of new ten tolmetin hydrazide derivatives, 
N-Alkyl/Arylsubstituted-2-{[1-methyl-5-(4-methylbenzoyl)-
1H-pyrrol-2-yl]acetyl}hydrazinecarbothioamides [4a-j] have 
been synthesized in this study. The structures of the new 
compounds were determined by spectral (FT-IR, 1H-NMR, 
13C-NMR and 2D-NMR) methods and their purity were 
proven by elemental analysis and TLC. Tolmetin [1] and N-(4-
fluorophenyl)-2-{[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-
2-yl]acetyl}hydrazinecarbothioamide [4d] were evaluated for 
in vitro using the MTT colorimetric method for anticancer 
activity. Androjen-independed human prostate cancer cell line 
PC-3 (ATCC, CRL-1435) , human colon cancer cell lines HCT-
116 (ATCC, CCL-247) and HT-29 (ATCC, HTB-38) were used 
in this study. Compound 4d exhibited anticancer activity against 
PC-3 whereas Tolmetin showed minor activity comparing to 
compound 4d. 




yl] acetic acid is a non-steroidal anti-inflammatory drug. 
In addition, it has been reported to prevent proliferation of 
colon cancer cells (1) and inhibit the β-catenin functions 
(2). Duffy and co-workers evaluated that tolmetin and other 
(NSAID)s have effects on increasing the cytotoxic activity 
of the anti-cancer drugs (3). Thiosemicarbazides, which 
are intermediate products of the synthesis for bioactive 
heterocyclic compounds, have taken attention of the 
researchers because of their clinical use and diverse biological 
activities (4-14) (Fig 1). In this work, we synthesized novel 
ten tolmetin thiosemicarbazide derivatives (4a-j) and 
investigated their anticancer activity against cancer cell lines. 
The characterization of these compounds were identified 
with the help of elementel analysis, FT-IR, 1H-NMR, 
13C-NMR and 2D-NMR spectral data while their purities 
were analyzed by thin layer chromatography (TLC).
Dadaş et al.
Synthesis and Anticancer Activity of Some Novel Tolmetin Thiosemicarbazides Marmara Pharm J 19: 259-267, 2015260
















































Br  (7 )                                     




















(8 )  







































R (1 4 )  
Fig 1. Some bioactive thiosemicarbazides. 
EXPERIMENTAL
Chemistry
Tolmetin sodium was generously provided by Santa Farma 
Pharmaceuticals (Istanbul, Turkey). All chemicals were 
purchased from Merck, Sigma-Aldrich, or Fluka. Reactions 
were monitored by TLC on silica gel plates purchased from 
Merck. Melting points of the synthesized com pounds were 
determined in a Thermoscientific IA 9300 melting point 
apparatus and are uncorrected. The purity of the com pounds 
was checked on TLC plates precoated with silica gel G using 
the solvent systems M1 (petroleum ether/acetone 50:50 v/v), 
M2 (petroleum ether/acetone 30:70 v/v). The spots were 
located under UV light (254 nm) (t = 21 °C). Elemental 
analyses were performed on a CHNS-932 (LECO). FT-
IR spectra were recorded on a Shimadzu FT-IR-8400S 
spectrophotometer. 1H-NMR and 13C-NMR spectra were 
recorded on BRUKER 300 MHz (4a, 4b, 4c, 4d, 4i), 600 
MHz (4e, 4f, 4g, 4h, 4j) and 75 MHz Ultrashield TM. NMR 
spectrometers using DMSO-d6 as solvent. Chemical shifts (d) 
are reported in parts per million (ppm). Data are reported as 
follows: chemical shift, multiplicity (s: singlet, d: doublet, m: 
multiplet and t: triplet, bs: broad singlet, b: broad, ss: singlet-
singlet) coupling constants (Hz), integration.
Preparation of 2-[1-Methyl-5-(4-methylbenzoyl)-
1H-pyrrol-2-yl]acetic acid [1], Methyl 2-[1-methyl-
5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetate [2] and 
2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]
acetohydrazide [3]
Compounds [1-3] were prepared as described previously 
(15,16).
General procedure for the synthesis of N-Alkyl/
Arylsubstituted- 2-{[1-methyl-5-(4-methylbenzoyl)-1H-
pyrrol-2-yl]acetyl}hydrazinecarbothioamides [4a-j]
Compound 3 (0.001 mol) was dissolved in ethanol (10 ml) 
and equimolar amounts of appropriate aliphatic/aromatic 
isothiocyanates in absolute ethanol was heated under reflux 
for 2 to 6 hrs. The obtained precipitate was filtered off, dried, 
and recrystallized twice from ethanol.
N-methyl-2-{[1-methyl-5-(4-methylphenyl)carbonyl]-1H-
pyyrol-2-yl}acetyl)hydrazinecarbothioamide (4a) [SGK 
521]
Light yellow solid. MW: 344.1306 g/mol. m.p. 160 ° C. Yield 
96.77%. Rf x 100 value: 60 (M2). FT-IR (vmax, cm
-1): 3535 
(Amide N-H), 1680 (C=O), 1257 (C=S). 1H NMR (300 MHz, 
DMSO-d6): δ (ppm): 1.05 (t, CH3, peak of ethanol held by the 
molecule); 2.38 (s, 3H, Ar-CH3), 2.88 (d, 3H, CS-NH-CH3), 
3.66 (s, 2H, -CH2-C=O), 3.85 (s, 3H, -N-CH3) 3.55 (CH2 peak 
of ethanol held by the molecule); 4.26 (–OH, peak of ethanol 
held by the molecule); 6.12 (d, 1H, pyrrol H3, J=4.2 Hz); 6.56 
(d, 1H, pyrrol H4,  J=4.2 Hz) 7.30 (d, 2H, o-protons, Ar-CH3, 
J= 8.1 Hz), 7.61 (d, 2H, m-protons, Ar-CH3, J= 8.1 Hz), 8.01 
(s, 1H, CS-NH-CH3), 9.27, 9.35 (bs, 1H, -CO-NH-NH-CS 
and NH-C-SH), 10.004 (bs, 1H, NH-C=O). Anal calcd. for 
C17H20N4O2S. 1/2 C2H5OH: C, 58.85; H, 6.27; N, 15.26; S, 
8.72%. Found: C, 58.66; H, 6.219; N, 15.41; S, 8.96%.
N-ethyl-2-({1-methyl-5-[(4-methylphenyl)carbonyl]-1H-
pyrrol-2-yl}acetyl)hydrazinecarbothioamide (4b) [SGK 
522]
Lighy cream solid. MW: 358.1463 g/mol. m.p. 169-170 ° C. 
Yield 87 %. Rf x 100 value: 59 (M2). FT-IR (vmax, cm
-1): 3215 
(Amide N-H), 1678 (C=O), 1263 (C=S). 1H NMR (300 MHz, 
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DMSO-d6): δ (ppm): 1.06 (t, 3H, -NH-CH2-CH3); 2.37 (s, 
3H, Ar-CH3); 3.45 (–NH-CH2-CH3, in solvent peak); 3.66 (s, 
2H, -CH2-C=O); 3.85 (s, 3H, -N-CH3 ); 6.08 (d, 1H, pyrrol 
H3; J=4.0 Hz) 6.56 (d, 1H, pyrrol H4; J=4.0 Hz); 7.46 (d, 2H, 
o-protons, Ar-CH3,  J=8.1 Hz); 7.61 (d, 2H, m-protons, Ar-
CH3,  J=8.1 Hz); 8.02 (t, 1H, -NH-CH2-CH3); 9.21, 9.36 (bs, 
1H, -NH-CS-NH- and -NH-C-SH); 9.98 (b, 1H, -NH-C=O). 
Anal calcd. for C18H22N4O2S: C, 60.31; H, 6.19; N, 15.63; S, 




Grey solid. MW: 406.1463 g/mol. m.p. 170 ° C. Yield 98 
%. Rf x 100 value: 49 (M2). FT-IR (vmax, cm
-1): 3329-3200 
(Amide N-H), 1654 (C=O), 1267 (C=S). 1H NMR (300 MHz, 
DMSO-d6): δ (ppm): 2.38 (s, 3H, Ar-CH3); 3.72 (s, 2H, -CH2-
C=O); 3.88 (s, 3H, -N-CH3); 6.15 (d, 1H, pyrrol H3, J=3.9 Hz); 
6.58 (d, 1H, pyrrol H4,  J=3.9 Hz); 7.31 (d, 2H, o-protons, Ar-
CH3,  J= 8.7 Hz); 7.62 (d, 2H, m-protons, Ar-CH3,J= 8.1 Hz); 
7.15-7.20; 7.35-7.45 (m, 5H, Ar-H); 9.52 (s, 1H,-NH-Ar); 9.66, 
9.74 (bs, 1H, -NH-CS-NH- and -NH-C-SH); 10.24 (s, 1H, 
-NH-C=O). Anal calcd. for C22H22N4O2S: C, 65.00; H, 5.46; N, 
13.78; S, 7.89%. Found: C, 64.64; H, 5.73; N, 13.67; S, 7.52%.
N - ( 4 - f l u o r o p h e n y l ) - 2 - ( { 1 - m e t h y l - 5 - [ ( 4 -
methylphenyl)c arb onyl]-1H-py rrol-2-y l}acety l) 
hydrazinecarbothioamide (4d) [SGK 524]
Light purple solid. MW: 424.1369 g/mol. m.p. 206-208 ° 
C. Yield 87 %. Rf x 100 value: 52 (M2). FT-IR (vmax, cm
-1): 
3553 (Amide N-H), 1651 (C=O), 1269 (C=S). 1H NMR (300 
MHz, DMSO-d6): δ (ppm): 2.39 (s, 3H, Ar-CH3), 3.73 (s, 2H, 
-CH2-C=O), 3.89 (s, 3H, N-CH3), 6.16 (d, 1H, pyrrol H3,  J=3 
Hz), 6.58 (d, 1H, pyrrol H4, J=3 Hz), 7.15 ( t, 2H, o-protons, 
4-fluorophenyl, J=9 Hz), 7.37-7.59 (m, Ar-H), 9.71 (s, 2H, 
NHCSNH), 10.24 (s, 1H, NH-C=O). 13C-NMR (75 MHz) 
(DMSO-d6/TMS) δ ppm:  21.52 (C-29), 32.35 (C-6), 33.53 
(C-7), 109.60 (C-3), 110.01 (C-4), 115.29 (C-25, C-27), 
122.16 (C-24, C-28), 128.59 (C-5), 129.20 (C-18, C-20), 
129.42 (C-17, C21), 130.74 (C-2), 135.85 (C-23), 137.25 (C-
16), 137.48 (C-26), 141.98 (C-19), 161 (thiosemicarbazide 
C=S), 168 (thiosemicarbazide C=O) 184.87 (C-10). D2O 
(600 MHz) (D2O/TMS) δ ppm: 2.34 (s, 3H, Ar-CH3), 3.71 
(s, 2H, -CH2-C=O), 3.82 (s, 3H, N-CH3), 6.14 (d, 1H, pyrrol 
H3, J=3.6 Hz), 6.56 (d, 1H, pyrrol H4, J=3.6 Hz), 7.15 ( t, 2H, 
o-protons, 4-fluorophenyl, J=9 Hz), 7.37-7.59 (m, Ar-H). 
Thiosemicarbazide protones were exchanged with doterium. 
Anal calcd. for C22H21FN4O2S: C, 62.25; H, 4.99; N, 13.20; S, 
7.55%. Found: C, 62.06; H, 5.05; N, 12.85; S, 6.97%
N - ( 4 - m e t h o x y p h e n y l ) - 2 - ( { 1 - m e t h y l - 5 - [ ( 4 -
methylphenyl)carbonyl]-1H-pyrrol-2-yl} acetyl)
hydrazinecarbothioamide (4e) [SGK 525]
Light yellow solid. MW: 436.1569 g/mol. m.p. 173-174 ° C. 
Yield 50 %. Rf x 100 value: 46 (M2). FT-IR (vmax, cm
-1): 3396-
3344 (Amide N-H), 1656 (C=O), 1246 (C=S). 1H NMR (600 
MHz, DMSO-d6): δ (ppm): 2.39 (s, 3H, Ar-CH3); 3.72 (s, 2H, 
-CH2-C=O); 3.76 (s, 3H, -N-CH3); 3.88 (s, 3H, -O-CH3); 6.15 
(d, 1H, pyrrol H3,  J=4.2 Hz); 6.58 (d, 1H, pyrrol H4, J=4.2 
Hz); 6.91 (d, 2H, o-protons, Ar-OCH3, J=9 Hz); 7.25 (d, 2H, 
m-protons, Ar-OCH3, J=9 Hz); 7.32 (d, 2H, o-protons, Ar-
CH3, J=7.8 Hz); 7.62 (d, 2H, m-protons, Ar-CH3, J=7.8 Hz); 
9.56 (bs, 1H, -NH-Ar), 9.60 (bs, 1H, -NH-CS-NH-); 10.20 
(s, 1H, -NH-C=O). Anal calcd. for C23H24N4O3S: C, 63.28; H, 
5.54; N, 12.83; S, 7.35%. Found: C, 63.27; H, 5.16; N, 12.43; 
S, 7.50%.
N - ( 4 - c h l o r o p h e n y l ) - 2 - ( { 1 - m e t h y l - 5 - [ ( 4 -
methylphenyl)carbonyl]-1H-pyrrol-2-yl} acetyl)
hydrazinecarbothioamide (4f) [SGK 526]
White solid. MW. 463.9799 g/mol. m.p. 203-205 ° C. Yield 
82.4 %. Rf x 100 value: 56 (M2). FT-IR (vmax, cm
-1): 3396-
3205 (Amide N-H), 1656 (C=O), 1267 (C=S). 1H NMR (600 
MHz, DMSO-d6): δ (ppm): 1.33 (t, CH3, peak of ethanol held 
by the molecule); 2.39 (s, 3H, Ar-CH3,); 3.55 (CH2, peak 
of ethanol held by the molecule); 3.73 (s, 2H, -CH2-C=O,); 
3.88 (s, 3H, -N-CH3); 4.5 (–OH, peak of ethanol held by the 
molecule); 6.15 (d, 1H, pyrrol H3, J=4.2 Hz); 6.58 (d, 1H, 
pyrrol H4,  J=4.2 Hz); 7.31 (d, 2H, o-protons, Ar-CH3, J=7.8 
Hz); 7.40-7.48 (m, 4H, Ar-H);  7.63 (d, 2H, m-protons, Ar-
CH3, J=7.8 Hz); 9.53, 9.77 (bs,  2H, NH-CS-NH,); 10.25 (s, 
1H, NH-C=O). Anal calcd. for C22H21ClN4O2S.1/2 C2H5OH: 
C, 59.54; H, 5.21; N, 12.08; S, 6.91%. Found: C, 59.80; H, 5.04; 
N, 12.09; S, 6.71%.
N - ( 4 - n i t r o p h e n y l ) - 2 - ( { 1 - m e t h y l - 5 - [ ( 4 -
methylphenyl)carbonyl]-1H-pyrrol-2-yl} acetyl)
hydrazinecarbothioamide (4g) [SGK 527]
Yellow solid. MW. 460.5058 g/mol. m.p. 207-208 ° C. Yield 
88 %. Rf x 100 value: 64 (M2). FT-IR (vmax, cm
-1): 3395-3333 
(Amide N-H), 1680 (C=O), 1267 (C=S). 1H NMR (600 MHz, 
DMSO-d6): δ (ppm): 2.39 (s, 3H, Ar-CH3); 3.75 (s, 2H, -CH2-
C=O); 3.89 (s, 3H, -N-CH3); 6.17 (d, 1H, pyrrol H3, J=4.2 
Hz); 6.59 (d, 1H, pyrrol H4, J=4.2 Hz); 7.31 (d, 2H, o-protons, 
Ar-CH3,  J=7.8 Hz); 7.63 (d, 2H, m-protons, Ar-CH3, J=7.8 
Hz); 7.90 (d, 2H, m-protons, Ar-nitro, J=9 Hz); 8.23 (d, 2H, 
o-protons, Ar-nitro, J=7.8 Hz); 10.09 (bs, 1H, -NH-Ar), 10.32 
(bs, 1H, -NH-CS-NH-); 10.50 (bs, 1H, -NH-C=O). Anal 
calcd. for C22H21N5O4S.1/2 H2O: C, 57.38; H, 4.82; N, 15.21; 
S, 6.96%. Found: C, 57.08; H, 4.46; N, 14.89; S, 6.68%.
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N - ( 2 , 4 - d i c h l o r o p h e n y l ) - 2 - ( { 1 - m e t h y l - 5 - [ ( 4 -
methylphenyl)carbonyl]-1H-pyrrol-2-yl} acetyl)
hydrazinecarbothioamide (4h) [SGK 528]
White solid. MW. 498.4250 g/mol. m.p. 170-172° C. Yield 
87.6 %. Rf x 100 value: 55 (M2). FT-IR (vmax, cm
-1): 3363 
(Amide N-H), 1647 (C=O), 1265 (C=S). 1H NMR (600 MHz, 
DMSO-d6): δ (ppm): 1.2 (–CH3, peak of ethanol held by the 
molecule); 2.39 (s, 3H, Ar-CH3); 3.54 (–CH2- ,peak of ethanol 
held by the molecule); 3.73 (s, 2H, -CH2-C=O); 3.87 (s, 3H, 
-N-CH3); 4.45 (–OH peak of ethanol held by the molecule); 
6.15 (d, 1H, pyrrol H3, J=3.6 Hz); 6.58 (d, 1H, pyrrol H4, 
J=4.2 Hz); 7.31 (d, 2H, o-protons, Ar-CH3, J=7.8 Hz); 7.63 
(d, 2H, m-protons, Ar-CH3, J=7.8 Hz); 7.42-7.45 (m, 2H, Ar-
H); 7.69-7.72 (m, 1H, Ar-H); 9.27 (s, ¼ H, NH-CS-NH-Ar); 
9.59,  9.89 (ss, 1H, NH-C=S and NH-C-SH); 10.32 (s, 1H, 
NH-C=O). Anal calcd. for C22H20Cl2N4O2S.1/2 C2H5OH: C, 
55.42; H, 4.65; N, 11.24; S, 6.43%. Found: C, 56.15; H, 4.16; 
N, 11.52; S, 6.17%.
N-(benzyl)-2-({1-methyl-5-[(4-methylphenyl)carbonyl]-
1H-pyrrol-2-yl} acetyl)hydrazinecarbothioamide (4i) 
[SGK 529]
White solid. MW. 420.527 g/mol. m.p. 203-205° C. Yield 
96.42 %. Rf x 100 value: 64 (M2). FT-IR (vmax, cm
-1): 3286-
3138 (Amide N-H), 1680 (C=O), 1263 (C=S). 1H NMR (300 
MHz, DMSO-d6): δ (ppm): 2.38 (s, 3H, Ar-CH3), 3.67 (s, 2H, 
-CO-CH2), 3.83 (s, 3H, -N-CH3), 4.75 (d, 2H, -NH-CH2-Ar), 
6.12 (d, 1H, pyrrol H3; J=3.9 Hz), 6.56 (d, 1H, pyrrol H4; J= 
4.2 Hz), 7.21-7.63 (m, 9H, Ar-H), 8.57 (s, 1H, CS-NH-CH2-
Ar), 9.42 (s, 1H, NH-NH-CS-NH ), 10.08 (bs, 1H, CO-NH-). 
Anal calcd. for C23H24N4O2S: C, 65.69; H, 5.75; N, 13.32; S, 
7.62%. Found: C, 65.24; H, 5.98; N, 13.17; S, 7.42%.
N - ( 4 - b r o m o p h e n y l ) - 2 - ( { 1 - m e t h y l - 5 - [ ( 4 -
methylphenyl)carbonyl]-1H-pyrrol-2-yl} acetyl)
hydrazinecarbothioamide (4j) [SGK 530]
Dark White solid. MW. 484.0568 g/mol. m.p. 204-205 ° C. 
Yield 92.04 %. Rf x 100 value: 48 (M2). FT-IR (vmax, cm
-1): 
3288 (Amide N-H), 1672 (C=O), 1257 (C=S). 1H NMR (600 
MHz, DMSO-d6): δ (ppm): 2.39 (s, 3H, Ar-CH3); 3.73 (s, 
2H, -CH2-C=O); 3.88 (s, 3H, -N-CH3); 6.15 (d, 1H, pyrrol 
H3, J=4.2 Hz); 6.59 (d, 1H, pyrrol H4, J=4.2 Hz); 7.31 (d, 2H, 
o-protons, Ar-CH3,  J=8.4 Hz); 7.44-7.54 (m, 4H, Ar-H) ;7.63 
(d, 2H, m-protons, Ar-CH3, J=7.8 Hz); 9.53; 9.78 (s, 2H, 
-NH-CS-NH-Ar); 10.25 (d, 1H, NH-C=O). Anal calcd. for 
C22H21BrN4O2S: C, 54.44; H, 4.36; N, 11.54; S, 6.61%. Found: 
C, 54.73; H, 4.15; N, 11.44; S, 6.31%.
Biological Activity
Cell Treatment:
Androjen-independed human prostate cancer cell line PC-3 
(ATCC, CRL-1435), human colon carcinoma cell lines HCT-
116 (ATCC, CCL-247) , HT-29 (ATCC, HTB-38) and mouse 
embriyonic fibroblast cell line NIH3T3 (ATCC, CRL-1658) 
were maintained in Dulbecco modified Eagle’s medium 
(DMEM) supplemented with 10% FBS and 1% penicilin/
streptomycin in the presence of 5% CO2 in air at 37 °C. 
Tolmetin and compound 4d were dissolved in DMSO and 
the cells were treated with increasing doses of compounds 
for 24 h in 37 °C.
Cell Viability Assay: 
Cell viability was determined by the MTT assay method. 
Briefly, PC-3 cells (1x104 cells/well) were seeded into 96-well 
plates and incubated for 24 h at 37°C in CO2 incubator. Then, 
the cells were grown in the absence or presence of increasing 
doses of tolmetin and compound 4d at 37°C. After 24 h 
treatment, the media was removed and then 10 μL of MTT 
(5 mg/mL in phosphate-buffered saline) was added to each 
well for an additional 4 hours. The precipitated formazan 
was dissolved in 100 μL of 10 % SDS and the absorbance was 
taken at 570 nm. The percentage of viability was calculated 
as the following formula: (viable cells)%=(OD of treated 
sample/OD of untreated sample)×100.
RESULTS AND DISCUSSION
Synthesis of Tolmetin thiosemicarbazides 
Tolmetin, 2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-
2-yl]acetic acid was chosen as the starting compound to 
design several novel thiosemicarbazides. As shown in the 
synthesis scheme (Fig 2), tolmetin was first synthesized from 
tolmetin sodium dihydrate by hydrolysing the dihydrate 
in conditions. Methyl 2-[1-methyl-5-(4-methylbenzoyl)-
1H-pyrrol-2-yl]acetate  [2] has been synthesized from 
tolmetin [1] with methanol and few drops of concentrated 
sulfuric acid. 2-[1-Methyl-5-(4-methylbenzoyl)-1H-
pyrrol-2-yl]acetohydrazide [3] was synthesized from 
compound [2], which is an ester, with hydrazine hydrate 
and methanol. N-Alkyl/Arylsubstituted-2-{[1-methyl-
5-(4-methylbenzoyl)-1H-pyrol-2-yl]acetyl}hydrazine 
carbothioamides [4a-j] were synthesized with the reaction 
of compound [3] and substituted alkyl/aryl isothiocyanates. 
The synthesized compounds were identifed by FT-IR, 
1H-NMR, 13C-NMR and 2D-NMR (only 4d) and their purity 
were proven by elemental analysis and TLC.
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i: H2O/HCl;  ii: CH3OH / H2SO4 ; iii: NH2NH2.H2O ; iv: A-N=C=S /EtOH 
 
Comp Lab Code A Comp Lab Code A 
4a SGK 521 Methyl 4f SGK 526 4-Chlorophenyl 
4b SGK 522 Ethyl 4g SGK 527 4-Nitrophenyl 
4c SGK 523 Phenyl 4h SGK 528 2,4-Dichlorophenyl 
4d SGK 524 4-Fluorophenyl 4i SGK 529 Benzyl 
4e SGK 525 4-Methoxyphenyl 4j SGK 530 4-Bromophenyl 
 
 Fig 2. Synthesis of tolmetin thiosemicarbazides [4a-j]
2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]
acetohydrazide was synthesized by Koç and co-workes (15), 
previously and –NH2 protones of hydrazide were reported in 
4.27 ppm. 1H-NMR spectrum of the compounds 4a-j proves 
the dissappearence of –NH2 protones which belong to –
CONHNH2 functional group. N1, N2 and N4 protones which 
prove the presence of thiosemicarbazides were detected in 
1H-NMR spectrum (Fig 3) and the information given is 
supported by the literature. (17-22).  














Fig 3. N1, N2 ve N4 protons of tolmetin thiosemicarbazides
Thiosemicarbazide protones were detected as follows; 
N1; 9.98-10.32 ppm, N2; 9.21-10.50 ppm, respectively. N4 
protones were detected in different ppm values as this data 
can change depending on the substituent which can have 
aryl or alkyl functionality. The ppm values of N4 protones 
is known to be in the aromatic field or outside of the 
aromatic field. Compounds 4a-b bearing methyl and ethyl 
substituted, their N4 protones were detected at 8.01-8.02 
ppm. Other compounds bearing phenyl, 4-fluorophenyl, 
4-methoxyphenyl, 4-chlorophenyl, 4-nitrophenyl, 
2,4-dichlorophenyl, benzyl and 4-bromophenyl substituted, 
their N4 protones were detected at 8.57-9.78 ppm. N4 proton 
of compound 4h has partly exchanged with doterium. Ethyl 
derivative compound 4b was studied 1H-NMR at 300 MHz 
in DMSO-d6 and the ethyl N-CH2 peak was overlaped in the 
solution peak. 
According to the 1H-NMR of results some compounds (4a, 
4c, 4e, 4f, 4h), it was determined that these compounds 
undergo thione-thiol tautomerism (Fig 4).
 
 


















Fig 4. Thione-thiol tautomerism of tolmetin 
thiosemicarbazides
In addition, -NH proton of compound 4d was observed to 
exchange with D2O in the spectrum (Fig 5).
 
 
Fig 5. D2O spectrum of compound 4d 
 
Fig 5. D2O spectrum of compound 4d
Compound 4d was chosen as the prototype for the 13 C NMR 
spectrum. The presence of C=O and C=S carbons in 13C-NMR 
spectrum proves the synthesis of thiosemicarbazide. C=O 
and C=S peak values can be seen in Fig 6. According to 
both HMBC and 13C-NMR data, C=O and C=S peaks were 
observed at 168 ppm and 161 ppm, respectively. (Fig 6-7).
 



























































Fig 6. 13C-NMR spectrum data of compound 4d
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Fig  7. HMBC spectrum of compound 4d 
 
Fig  7. HMBC spectrum of compound 4d
Biological results
Küçükgüzel and co-workers (16) studied the anticancer 
activity of Tolmetin [1] and N’-[(2,6-dichlorophenyl)
methylidene]-2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-
2-yl]aceto hydrazide against HCT-116 (ATCC, CCL-247) and 
HT-29 (ATCC, HTB-38) human colon cancer cell lines, using 
MTT assay. The results revealed that tolmetin hydrazone 
showed anticancer activity againts HT-29 colon cancer cell 
line (dose depended) with IC50 value of 76 µM. Tolmetin 
hydrazone was then used in further tests to investigate the 
apoptotic effect on HT-29 cancer cell line. Apoptosis is 
known to be an important mechanism of cancer growth 
and therefore, caspase 3, caspase 8 and caspase 9 enzyme 
levels were observed in apoptotic pathway. This study proves 
that tolmetin hydrazone triggers apoptosis using caspase 8 
pathway in HT-29 cancer cell line.
Prostate cancer is known to be the second cancer disease 
after lung cancer with the insidance of 24.33/100.000 in 
our country. It is also reported as a common cancer type 
in USA and Europe  (23). Demertzi et al. (24) reported 
the antineoplastic activity of thiosemicarbazones (TSC). 
TSC can bind the heavy metals with its two nitrogen and 
one sulphur atom, occuring a triple chelation. TSCs were 
reported to be strong inhibitors of ribonucleotite reductase 
(RR) which reduces ribonucletites to deoxyribonucletites 
(25). Ribonucleotide reductase is an important enzyme in 
cell division and tumor growth. TSCs, RR inhibitors, inhibits 
the DNA synthesis and DNA repair; therefore they show 
antineoplastic activity. (26, 27). Ferrari et al. (28)  reported 
the biological activities of TSCs depends on the Van der 
Walls and hydrojen bonds between the molecule and DNA. 
Beytur et al. (29) studied the effects of TSCs and their metal 
complexes on LNCaP cell viability and found out all the 
metal complexes (except Ni complex) have dose depended 
effects on LNCaP cells. However, they did not observe any 
activity againts PC-3 cell lines (except the 25 and 50 μM 
concentrations). The antitumor activity of TSCs againts 




[4d] bearing thiosemicarbazide and fluoro substitution and 
Tolmetin were chosen for the anticancer activity test in M.U. 
Faculty of Pharmacy, Department of Biochemistry. HCT-
116 (ATCC, CCL-247) and HT-29 (ATCC, HTB-38) human 
colon cancer cell line and PC-3 (ATCC, CRL-1435)  cell 
lines were used in this study. MTT assay results shows that, 
tolmetin thiosemicarbazide [4d] showed anticancer activity 
(dose depended) only to androjen independed prostate 
cancer cell line PC-3 with IC50 value of 184.5 µM (Fig 8). 
Besides, tolmetin and compound 4d cytotoxicity tests were 
carried out with NIH-3T3 fibroblast cells (Fig 9).
 
Fig 8. Growth inhibition of Tolmetin and 4d on PC-3 cells 
 
 




Fig 9. Cell viability of Tolmetin and 4d on NIH-3T3 fibroblast cells 
 
 
Fig 9. Cell viability of Tolmetin and compound 4d on NIH-
3T3 fibroblast cells
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Uncontrolled cell growth is not enough for cancer 
formation. The cell should gain the ability of invasion 
and metastasis. Extracellular matrix members (ECM) is 
the primer barrier molecule for the inhibition of tumor 
growth and tumor invasion (30). ECM has the structue of 
proteins and proteoglycans. Besides the ability of structural 
support of the cells, ECM has biological activity on cell 
proliferation, cell differantiation, migration and adhesion, 
tissue morphogenesis. Cancer cells use metalloproteinases 
to get over that barrier. In order to complete invasion or 
metastasis, cancer cells should destroy the ECM molecules. 
Matrix metalloproteinases (MMP) are extracellular proteases 
that consist of 28 different enzymes and responsible for 
physiological and pathological tissue distruction. These 
enzymes were first identified by Jerome Gross and Charles 
Lapiere in 1962  (31). 
The destruction of MMP, ECM, can be seen in different 
physiological and pathological situations (32). MMPs belong 
to neutral endopeptidases enzyme family and consist zinc 
ion, they also have the ability of destroying whole ECM 
members. Among these members, MMP-2 and 9 levels 
significantly increase in metastatic prostate cancer (33) These 
two enzyme levels decrease after the treatment and therefore, 
they can be evaluated for the efficacy of the treatment.
MMP inhibitors pharmacologically are devided into three 
different groups as peptites and non-peptite collagen-
like inhibitors, Tetracycline and Biphosphonates. In early 
1980’s, the first synthetic MMP inhibitör was developed as 
pseudopeptite derivative that imitate the collagen structure 
in MMP seperation area. These inhibitors reversibly bind the 
MMP’s active side. They also create chelation with MMP’s 
active zinc ion with their hydroxamic acid. New molecules 
are developed from the derivatives of Tetracyclines and they 
have the ability of inhibiting MMPs rather than showing 
antibacterial activity. Tetracyclines could be preventing the 
avidity to zinc atom or they could inhibit the regulation of 
MMP during the transcription. Metastat (Col-3), minocyclin 
and doxycycline are the examples of these inhibitors (34).
Küçükgüzel and co-workers (16) synthesized N’-
[(2,6-dichlorophenyl)methyliden]-2-[1-methyl-5-(4-
methylbenzoyl)-1H-pyrrol-2-yl]acetohydrazide and found 
activity againts HT-29 colon cancer cell line with IC50 value 
of 76 µM. This information showed, against colon cancer 
cell line anticancer activiy of tolmetin maintains whereas the 
thiosemicarbazide molecule from the same compound have 
no activity againts colon cancer, instead, it shows activity 
againts prostate cancer cells. We can conclude that, the 
electrophilic compounds in the cell bind the sulphur atom 
in the molecule. Furthermore, thiosemicarbazide may be 
creating a chelation with the zinc ion in the metalloproteinease 
enzyme as M. Öncel reported before (34). (Fig 10).
 













Fig 10. Proposed chelation with zinc ion and 
thiosemicarbazide 
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Bazı Yeni Tolmetin Tiyosemikarbazitlerinin Sentezi ve 
Antikanser Aktivitesi
ÖZET
Bu çalışmada, on adet tolmetin hidrazidi türevleri olan yeni 
N-Alkil/Arilsübstitue- 2-{[1-metil-5-(4-metilbenzoil)-1H-pi-
rol-2-il]asetil}hidrazinkarbotiyoamit [4a-j] bileşikleri sentez-
lenmiştir. Sentezlenen bileşiklerin yapıları spektral yöntemlerle 
(FT-IR, 1H-NMR, 13C-NMR ve 2D-NMR) aydınlatılmış ve saf-
lıkları elementel analiz ve TLC ile kanıtlanmıştır. Tolmetin [1] 
ve N-(4-fluorofenil)-2-{[1-metil-5-(4-metilbenzoil)-1H-pirol-
2-il]asetil}hidrazinkarbotiyoamit [4d] bileşikleri MTT kolori-
metrik yöntemi ile in vitro antikanser aktivite için değerlendi-
rilmiştir. Bu çalışmada androjene bağımlı olmayan kanser hücre 
hattı PC-3 (ATCC, CRL-1435) , insan kolon kanser hücre hatları 
HCT-116 (ATCC, CCL-247) ve HT-29 (ATCC, HTB-38) kulla-
nılmıştır. Bileşik 4d PC-3 kanser hücre hattına karşı antikanser 
aktivite gösterir iken, Tolmetin etken maddesi 4d bileşiğine kı-
yasla bu hücre hattına karşı daha az aktivite göstermiştir.
Anahtar kelimeler: Apoptoz, tolmetin, tiyosemikarbazit, 
PC-3, kolon kanser.
Dadaş et al.
Synthesis and Anticancer Activity of Some Novel Tolmetin Thiosemicarbazides Marmara Pharm J 19: 259-267, 2015266
REFERENCES
1. Hixson LJ, Alberts DS, Krutzsch M, Einsphar J, 
Brendel K. Gross PH, Paranka NS, Baier M, Emerson S, 
Pamukcu R, Burt RW. Antiproliferative effect of nonsteroidal 
antiinflammatory drugs against human colon cancer cells. 
Cancer Epidemiol Biomarkers  Prev 1994;3: 433-8.
2. Lu D, Cottam HB, Corr M, Carson DA. Repression 
of β-catenin function in malignant cells by nonsteroidal 
antiinflammatory drugs. Proc Natl Acad Sci 2005;102: 
18567-71.
3. Duffy CP, Elliott CJ, O’Connor RA, Heenan MM, 
Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O’Loughlin 
CM, NicAmhlaoibh R, Clynes M. Enhancement of 
chemotherapeutic drug toxicity to human tumour cells in 
vitro by a subset of non-steroidal anti-inflammatory drugs 
(NSAIDs).  Eur J Cancer 1998; 43:1250-9.
4. Kalyoncuoğlu N, Rollas S, Sür-Altıner D, Yeğenoğlu 
Y, Anğ Ö. 1-[p-(Benzoylamino)benzoyl]-4-substituted 
thiosemicarbazides: Synthesis and antibacterial and 
antifungal activities. Pharmazie 1992;47: 796-7.
5. Rollas S, Karakuş S, Durgun BB. Synthesis and 
Antimicrobial Activity of Some 1,4-Disubstituted 
Thiosemicarbazide and 2,5-Disubstituted 1,3,4-Thiadiazole 
Derivatives. Il Farmaco 1996;51: 811-4.
6. Al-Saadi MS, Faidallah HM, Rostom S, A. F. Synthesis 
and Biological Evaluation of Some 2,4,5-Trisubstituted 
Thiazole Derivatives as Potential Antimicrobial and 
Anticancer Agents. Arch Pharm Chem Life Sci 2008;341: 
424-34.
7. Sun Y, Wang W, Sun Y, Han M. Synthesis and biological 
evaluation of a novel stem/progenitor cells proliferation 
activator: 4-(4-(5-mercapto-1,3,4-oxadiazole-2-yl)phenyl)
thiosemicarbazie (Stemazole).  Eur J Med Chem 2011;46: 
2930-6. 
8. He J, Wang X, Zhao X, Liang Y, He H, Fu L. Synthesis 
and antitumor activity of novel quinazolinone derivatives 
containing thiosemikarbazide moiety. Eur J Med Chem 
2012;54: 925-30.
9. Çıkla P, Arora P, Basu A, Talele TT, Kaushik-Basu N, 
Küçükgüzel ŞG. Etodolac Thiosemicarbazides: a novel class 
of hepatitis C virus NS5B polymerase inhibitors. Marmara 
Pharm j 2013;17: 138-46.
10. Singhal S, Arora S, Agarwal S, Sharma R, Singhal N. A 
review on potential biological activities of thiosemicarbazides. 
World J Pharm and Pharm Sci 2013;2: 4661-81.
11. Siwek A, Staczek P, Wujec M, Bielawski K, Bielawska 
A, Paneth P. Cytotoxic effect and molecular docking of 
4-ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-
thiosemicarbazide-a novel topoisomerase II inhibitör. J Mol 
Mod 2013;19: 1319-24.
12. Arora S, Agarwal S, Singhal S. Anticancer Activities Of 
Thiosemicarbazides/Thiosemicarbazones: A Review. Int J 
Pharm Pharm Sci 2014;6.
13. Mavrova AT, Wessilinova D, Tsenov JA, Lubenov 
LA. Synthesis and antiproliferative activity of some 
new thieno[2,3-d]pyrimidin-4(3H)-ones containing 
1,2,4-triazole and 1,3,4-thiadiazole moiety. Eur J Med Chem 
2014;86: 676-83.
14. Ünver Y, Sancak K, Çelik F, Birinci E, Küçük M, Soylu 
S, Arslan Burnaz N. New thiophene-1,2,4-triazole-5(3)-ones: 
Highly bioactive thiosemicarbazides, structures of Schiff 
bases and triazoleethiols. Eur J Med Chem 2014;84: 639-50.
15. Koç D. Tolmetin Üzerinden Hidrazit-Hidrazonların 
Sentezi Ve Biyolojik Etkileri. M.Ü. Institute of Health 
Sciences, Master Degree Thesis, 2014, İstanbul (Advisor: 
Prof. Dr. Ş. Güniz Küçükgüzel).
16. Küçükgüzel ŞG, Koç D, Çıkla-Süzgün P, Özsavcı D, 
Bingöl-Özakpınar Ö, Mega-Tiber P, Orun O, Erzincan 
P, Erdem SS, Şahin F. Synthesıs of Tolmetın Hydrazide-
Hydrazones and Discovery of a Potent Apoptosis Inducer in 
Colon Cancer Arch Pharm (Weinheim) 2015; In Press.
17. Rollas S. Bazı l-aroil-4-alkil/ariltiyosemikarbazidler I. 
Doğa Bilim Derg 1983;7: 65-73.
18. Durgun BB, Rollas S, Apaydın S, Öztürk R. 
Synthesis and antimicrobial activity of some new 
1-[4-(4-fluorobenzoylamino)-benzoyl]-4-substituted 
thiosemicarbazides. Drug Metab Drug Interact 1995;12: 145-
50. 
19. Doğan HN, Rollas S, Erdeniz H. Synthesis, structure 
elucidation and antimicrobial activity of some 3-hydroxy-
2-naphthoic acid hydrazide derivatives. Il Farmaco 1998;53: 
462-7.
20. Küçükgüzel ŞG, Oruç EE, Rollas S, Şahin F, Özbek 
A. Synthesis, Characterisation and Biological Activity of 
Novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related 
compounds.  Eur J Med Chem 2002;37: 197-206.
21. Küçükgüzel ŞG, Kocatepe A, Clercq ED, Şahin F, Güllüce 
M. Synthesis and biological activity of 4-thiazolidinones, 
thiosemicarbazides derived from diflunisal hydrazide.  Eur J 
Med Chem 2006;41: 353-9.
22. Tatar E, Küçükgüzel İ, De Clercq, Şahin F, Güllüce M. 
Synthesis, characterization and screening of antimicrobial, 
antituberculosis, antiviral and anticancer activity of novel 
1,3-thiazolidine-4-ones derived from 1-[2-(benzoylamino)-
4-(methylthio)butyryl]-4-alkyl/arylalkyl thiosemicarbazides. 
Arkivov 2008;14: 191-210.
23. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J. Cancer 
Dadaş et al.
Synthesis and Anticancer Activity of Some Novel Tolmetin ThiosemicarbazidesMarmara Pharm J 19: 259-267, 2015 267
incidence and mortality patterns in Europe: Estimates for 40 
countries in 2012. Eur J Cancer 2013;49: 1374-1403.
24. Demertzi DK, Domopoulou A, Demertzis MA. 
Palladium (II) Complexes of 2-Acetylpyridine N(4)-
Methyl, N(4)-Ethyl and N(4)-Phenyl - Thiosemicarbazones. 
Crystal Structure of Chloro (2-Acetylpyridine N(4)-
Methylthiosemicarbazonato) Palladium (II). Synthesis, 
Spectral Studies, In vitro and In vivo Antitumour Activity. J 
Inorg Biochem 1997;68: 147-55.
25. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer 
statistics. CA Cancer J Clin 2000;50: 7-33.
26. Alvero AB, Chen W, Sartorelli AC, et al. Triapine 
(3-amino-2-carboxaldehyde thiosemicarbazone) Induces 
Apoptosis in Ovarian Cancer Cells. J Soc Gynecol Investig 
2006;13: 145-52.
27. Yu Y, Wong J, Lovejoy DB. Chelators at the cancer 
coalface: desferrioxamine to Triapine and beyond. Clin 
Cancer Res 2006;12: 6876-83.
28. Ferrari BM, Capacchi S, Pelosi G. Synthesis, Structural 
Characterization and Biological Activity of Helicin 
Thiosemicarbazone Monohydrate and a Copper (II) Complex 
of Salicylaldehyde Thiosemicarbazone. Inorg Chimica Acta 
1999;286: 134-41. 
29. Beytur A, Tekin S, Keleştimur T, Ergin Z, Sandal S. Yeni 
Sentezlenen Bir Tiyosemikarbazon Türevinin Prostat Kanseri 
Hücre Kültürleri Üzerine Antikanserojenik Özelliklerinin 
Belirlenmesi: In vitro Bir Çalışma. FÜ Sağ Bil Tıp Derg 
2011;25: 25-32.
30. Lu P, Weaver VM, Werb Z. The extracellular matrix: A 
dynamic niche in cancer progression J Biol 2012;196: 395-
406.
31. Gross J,     Lapiere CM. Collagenolytıc Actıvıty In 
Amphıbıan Tıssues: A Tıssue Culture Assay. Proc Natl Acad 
Sci USA 1962;48: 1014-22.
32. Itoh Y, Nagase H. Matrix metalloproteinases in cancer. 
Essays Biochem 2002;38: 21-36.
33. Zhang L,  Shi J,  Feng J,  Klocker H,  Lee C,  Zhang J. 
Type IV collagenase (matrix metalloproteinase-2 and -9) in 
prostate cancer. Prostate Cancer Prostatic Dis 2004;7: 327-32.
34. Öncel M. Matriks Metalloproteinazlar ve Kanser. Eur J 
Basic Med Sci 2012;2: 91-100.
